144 related articles for article (PubMed ID: 35226228)
1. IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4.
Huo J; Fu L; Jin M; Li Z; Zhang M
Invest New Drugs; 2022 Jun; 40(3):537-545. PubMed ID: 35226228
[TBL] [Abstract][Full Text] [Related]
2. IL-13 Contributes to Drug Resistance of NK/T-Cell Lymphoma Cells by Regulating ABCC4.
Ni M; Qin B; Xie L; Zhang X; Yang J; Lv H; Yang M; Zhang M
Biomed Res Int; 2018; 2018():2606834. PubMed ID: 30643796
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 reverses Adriamycin resistance in nasal NK/T-cell lymphoma via downregulation of ABCC4 and inactivation of the JAK2/STAT3/NF-κB/P65 pathway.
Gao M; Liu L; Zhang X; Li Z; Zhang M
Environ Toxicol Pharmacol; 2021 Jul; 85():103639. PubMed ID: 33771682
[TBL] [Abstract][Full Text] [Related]
4. ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target.
Zhang X; Zhao L; Li X; Wang X; Li L; Fu X; Sun Z; Li Z; Nan F; Chang Y; Zhang M
Leuk Res; 2015 Dec; 39(12):1448-54. PubMed ID: 26499190
[TBL] [Abstract][Full Text] [Related]
5. [14-3-3ζ protein mediates gemcitabine resistance in NK/T-cell lymphoma].
Qiu YJ; Zhang MZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):906-911. PubMed ID: 31856438
[No Abstract] [Full Text] [Related]
6. Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells.
He C; Liu B; Wang HY; Wu L; Zhao G; Huang C; Liu Y; Shan B; Liu L
BMC Cancer; 2022 Oct; 22(1):1100. PubMed ID: 36303126
[TBL] [Abstract][Full Text] [Related]
7. sATP‑binding cassette subfamily G member 2 enhances the multidrug resistance properties of human nasal natural killer/T cell lymphoma side population cells.
Wu S; Zhang X; Dong M; Yang Z; Zhang M; Chen Q
Oncol Rep; 2020 Oct; 44(4):1467-1478. PubMed ID: 32945520
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
Wang JH; Wang L; Liu CC; Xia ZJ; Huang HQ; Lin TY; Jiang WQ; Lu Y
Oncotarget; 2016 May; 7(20):29092-101. PubMed ID: 27093153
[TBL] [Abstract][Full Text] [Related]
9. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.
Haverkos BM; Pan Z; Gru AA; Freud AG; Rabinovitch R; Xu-Welliver M; Otto B; Barrionuevo C; Baiocchi RA; Rochford R; Porcu P
Curr Hematol Malig Rep; 2016 Dec; 11(6):514-527. PubMed ID: 27778143
[TBL] [Abstract][Full Text] [Related]
10. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up.
Wang L; Wang WD; Xia ZJ; Zhang YJ; Xiang J; Lu Y
Med Oncol; 2014 Mar; 31(3):860. PubMed ID: 24481637
[TBL] [Abstract][Full Text] [Related]
11. The Acetyltransferase KAT5 Inhibitor NU 9056 Promotes Apoptosis and Inhibits JAK2/STAT3 Pathway in Extranodal NK/T Cell Lymphoma.
Xu L; Qin Y; Liu M; Jiao J; Tu D; Zhang M; Yan D; Song X; Sun C; Zhu F; Wang X; Sang W; Xu K
Anticancer Agents Med Chem; 2022; 22(8):1530-1540. PubMed ID: 34503423
[TBL] [Abstract][Full Text] [Related]
12. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
[TBL] [Abstract][Full Text] [Related]
13. Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study.
Wang H; Wuxiao ZJ; Zhu J; Wang Z; Wang KF; Li S; Chen X; Lu Y; Xia ZJ
Leuk Lymphoma; 2015 Apr; 56(4):971-7. PubMed ID: 24991715
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.
Wang JH; Wang H; Wang YJ; Xia ZJ; Huang HQ; Jiang WQ; Lu Y
Oncotarget; 2016 Jun; 7(23):35412-22. PubMed ID: 27072578
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
Wei W; Wu P; Li L; Zhang ZH
Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of Clinical Efficacy and Influencing Factors of Gemcitabine-L-Asparaginase-Oxaliplatin Chemotherapy Scheme and Radiotherapy for Treatment of Early ENKTL Patients].
Qiu C; Wang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1420-1425. PubMed ID: 29070118
[TBL] [Abstract][Full Text] [Related]
17. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
[TBL] [Abstract][Full Text] [Related]
18. [Extranodal NK/T-cell lymphoma, nasal-type, revealed by cutaneous breast involvement].
Fréling E; Granel-Brocard F; Serrier C; Ortonne N; Barbaud A; Schmutz JL
Ann Dermatol Venereol; 2015 Feb; 142(2):104-11. PubMed ID: 25554664
[TBL] [Abstract][Full Text] [Related]
19. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.
Wang L; Wang ZH; Chen XQ; Li YJ; Wang KF; Xia YF; Xia ZJ
Cancer; 2013 Jan; 119(2):348-55. PubMed ID: 22811078
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.
Tsuyama N; Asaka R; Dobashi A; Baba S; Mishima Y; Ueda K; Oguchi M; Tsuji H; Hatake K; Takeuchi K
Hematol Oncol; 2018 Feb; 36(1):328-335. PubMed ID: 28695659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]